STATUS OF ORPHAN DRUGS AND REIMBURSEMENT RECOMMENDATIONS AND DECISIONS IN ANALYSED EUROPEAN COUNTRIES

被引：0
|
作者：
Kawalec, P. [1 ]
Malinowski, K. [1 ]
机构：
[1] Jagiellonian Univ, Coll Med, Krakow, Poland
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1450
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY133
引用
收藏
页码：A598 / A599
页数：2
相关论文
共 50 条
  • [41] Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries
    Kleijnen, S.
    Lipska, I.
    Alves, T. Leonardo
    Meijboom, K.
    Elsada, A.
    Vervoelgyi, V.
    d'Andon, A.
    Timoney, A.
    Leufkens, H. G.
    De Boer, A.
    Goettsch, W. G.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1768 - 1775
  • [42] AN EUROPEAN OVERVIEW OF THE FUTURE CHANGES IN EVIDENCE REQUIREMENTS FOR THE REIMBURSEMENT OF ORPHAN DRUGS-A STAKEHOLDER ANALYSIS
    Krueger, L. J.
    Tamminga, J. J.
    Wijnen, B.
    Hiligsmann, M.
    Evers, S. M.
    VALUE IN HEALTH, 2014, 17 (03) : A236 - A236
  • [43] ANALYSIS OF ANATOMICAL THERAPEUTIC CHEMICAL (ATC) CLASSIFICATION AND THERAPEUTIC AREA OF ORPHAN MEDICINAL PRODUCTS (OMP) VS REIMBURSEMENT FOR THESE DRUGS IN 11 EUROPEAN COUNTRIES
    Jakubowski, S.
    Kawalec, P.
    VALUE IN HEALTH, 2024, 27 (12) : S283 - S284
  • [44] Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
    Rinke van den Brink
    Orphanet Journal of Rare Diseases, 9 (Suppl 1)
  • [45] Pricing and reimbursement of orphan drugs: the need for more transparency
    Steven Simoens
    Orphanet Journal of Rare Diseases, 6
  • [46] Pricing and reimbursement of orphan drugs: the need for more transparency
    Simoens, Steven
    ORPHANET JOURNAL OF RARE DISEASES, 2011, 6
  • [47] TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5
    Prada, M.
    Berard, I
    Walzer, S.
    Darba, J.
    Greenwood, B.
    VALUE IN HEALTH, 2018, 21 : S264 - S264
  • [48] Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis
    Garattini, Livio
    Cornago, Dante
    De Compadri, Paola
    HEALTH POLICY, 2007, 82 (03) : 330 - 339
  • [49] Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs
    Denis, Alain
    Mergaert, Lut
    Fostier, Christel
    Cleemput, Irina
    Hulstaert, Frank
    Simoens, Steven
    PHARMACOECONOMICS, 2011, 29 (10) : 883 - 893
  • [50] Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs
    Alain Denis
    Lut Mergaert
    Christel Fostier
    Irina Cleemput
    Frank Hulstaert
    Steven Simoens
    PharmacoEconomics, 2011, 29 : 883 - 893
12345